<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3066">
  <stage>Registered</stage>
  <submitdate>27/01/2011</submitdate>
  <approvaldate>27/01/2011</approvaldate>
  <nctid>NCT01290042</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20101261</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 181
Other interventions - Placebo for AMG 181

Active Comparator: Placebo arm - Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

Active Comparator: Active arm - Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.


Treatment: drugs: AMG 181
Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

Other interventions: Placebo for AMG 181
Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the number of adverse events per subject, after multiple subcutaneous doses of AMG 181 in in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.</outcome>
      <timepoint>40 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To measure the area under the plasma concentration curve versus time of drug AMG 181.</outcome>
      <timepoint>29 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess receptor saturation percentages relative to baseline after multiple doses of AMG 181.</outcome>
      <timepoint>29 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate changes in peripheral blood T lymphocyte subsets counts relative to baseline after multiple doses of AMG 181.</outcome>
      <timepoint>29 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Body Mass Index (BMI) between 18 and 34 kg/m2

          -  Normal physical and neurological examination, clinical laboratory values and ECG

          -  Ulcerative Colitis Disease Activity Index (UCDAI, aka Mayo score) score of 4 to 10
             (inclusive), with a minimum sigmoidoscopy score of 1; (for subjects with ulcerative
             colitis)

          -  Crohn's Disease Activity Index (CDAI) score of &gt;150 and &lt; 450 at screening (for
             subjects with Crohn's disease)

          -  Additional inclusion criteria apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or evidence of a clinically significant disorder (including psychiatric),
             condition or disease that would pose a risk to subject safety or interfere with the
             study evaluations, procedures or completion

          -  History of malignancy of any type, other than in situ cervical cancer or surgically
             excised non-melanomatous skin cancers within the past 5 years

          -  Underlying condition(s) that predisposes the subject to infections

          -  Disease limited to the rectum, i.e. within 10 cm of the anal verge (for subjects with
             ulcerative colitis)

          -  Evidence of severe disease (as evidenced by an Hb concentration less or equal to
             10g/dL; toxic megacolon, or an UCDAI score greater than 10) (for subjects with
             ulcerative colitis)

          -  Subject has short bowel syndrome (for subjects with Crohn's disease)

          -  Presence of an ostomy (for subjects with Crohn's disease)

          -  Presence of a fistula (for subjects with Crohn's disease)

          -  Additional exclusion criteria apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC</recruitmentstate>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Prahran</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy
      subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's
      disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01290042</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>